Cic edizioni internazionali
Clinical Cases in mineral and bone metabolism

Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study

Original Article, 195 - 199
doi: 10.11138/ccmbm/2016.13.3.195
Tag this article
Abstract
Enhanced HTML Full text PDF
Introduction. Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. The best defense against osteoporosis in prostate cancer is to identify patients with a high risk for fracture during the first clinical visit, select an effective anti-osteoporosis agent, and advise the patient to change his lifestyle and diet to prevent further bone loss. New agents include denosumab, a human monoclonal antibody that inhibits the RANK ligand (RANKL).
RANKL promotes the formation, activity, and survival of osteoclasts and, thus, supports the breakdown of bone.
Purpose. This is a multicenter, randomized, double-blind prospective study on use of denosumab versus alendronate in the therapy of secondary osteoporosis related to ADT in prostate cancer patients in three European countries (Italy, France, Switzerland).
Patients and methods. In this 24-month observation study we enrolled 234 patients with diagnosis of osteoporosis underwent ADT for prostate cancer. All patients aged ≥55 years and had a dual-energy X-ray absorptiometry (DEXA) T-score <-1.0 (hip or spine, measured within last 2 years) and ≥ 1 fragility fracture. Patients were randomly assigned 1:1 to receive denosumab 60 mg subcutaneously every 6 months or alendronate (70 mg weekly) for 2 years. All patient received supplemental vitamin D (600 IU per day) and supplemental calcium to maintain a calcium intake of 1200 mg per day. Effectiveness of therapy in both groups (denosumab group and alendronate group) was assessed by changes in bone turnover markers (BTMs), Bone Mineral Density (BMD), fracture incidence, Visual Analogue Scale (VAS) score for back pain, and Short Form-8 (SF-8TM) health survey score for healthrelated quality of life (HRQoL). Percent changes from baseline in BTMs and BMD were assessed using the paired t test; a P-value 0.05). Mean changes in BMD at final follow-up differed significantly between two groups. BMD changes at the lumbar spine at 24 months were 5.6% with denosumab vs - 1.1% with alendronate (P<0.001). New vertebral fractures developed in fewer patients in the denosumab group than in the alendronate group during the 24-month period, although this difference was not significant (P=0.10). Back pain significantly (P<0.001) improved from baseline at all time points during the study in both study groups. SF-8 health survey scores significantly improved following treatment with both drugs. Incidence of adverse drug reactions were similar in both groups.
Conclusion. In our study denosumab and alendronate showed similar clinical efficacy in the therapy of ADT-related osteoporosis in men with prostate carcinoma; both drugs provided significant improvements in back pain and general health conditions. Denosumab showed significant increase of BTMs and BMD than alendronate with lower rate of new vertebral fractures.

Vol. XV (No. 1) 2018 January - April

  1. From the Editor-in-Chief
    Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.007
  2. The use of null-hypothesis significance testing: issues and solutions
    Gronchi G., Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.009
  3. Role of Mediterranean diet in bone health
    Migliaccio S., Marrocco C., Mocini E., Lenzi A., Greco E.A.
    doi: 10.11138/ccmbm/2017.15.1.016
  4. The Mediterranean diet for bone health in osteoporosis. Children and adolescents
    Pampaloni B., Quattrini S., Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.019
  5. Parmigiano Reggiano cheese: a super-food for bone health
    Pampaloni B., Cianferotti L., Ciampi V., Nocetti M., Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.029
  6. Pain from osteoporotic fractures: rationale of therapeutic options
    Hans G. Kress
    doi: 10.11138/ccmbm/2017.15.1.036
  7. New therapeutic strategies in the management of chronic pain related to osteoporosis
    Arghetti S., Magenta P., Racagni M.
    doi: 10.11138/ccmbm/2017.15.1.041
  8. Atypical femur fractures
    Cozzi Lepri A., Capone A., Del Prete A., Soderi S., Muncibì F., Civinini R.
    doi: 10.11138/ccmbm/2017.15.1.043
  9. Surgical strategies for high-energy fractures in patients with osteoporosis
    Cozzi Lepri A., Capone A., Del Prete A., Soderi S., Soderi S., Muncibì F., Innocenti M.
    doi: 10.11138/ccmbm/2017.15.1.060
  10. Sequential therapy: the way to go to prevent fragility fractures
    Gonnelli S., Alessandri M., Caffarelli C.
    doi: 10.11138/ccmbm/2017.15.1.066
  11. Atypical fractures following prolonged bisphosphonate use: a report of two cases
    Daniel-Lavee G., Nudelman P., Deltoff M., Shtarker H.
    doi: 10.11138/ccmbm/2017.15.1.070
  12. Osteoporosis treatment following a low trauma wrist fracture presenting to the Accident and Emergency Department from 2011 to 2015
    Sim Yeap S., Mat Akhir N.S., Thirunavukkarasu V., Thambiah S.C., Samsudin I.N., Zahari Sham S.Y., Balan P., Hew1 F.L., Chan S.P.
    doi: 10.11138/ccmbm/2017.15.1.074
  13. Low intestinal tract adenomatous polyps regression in FAP patients by dietary-induced erbeta upregulation
    Tonelli F., Fabbri S., Ficari F., Batignani G., Femia A.P., Caderni G., Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.079
  14. Calcific arteriolopathy beyond chronic kidney disease. The role of hemochromatosis and vitamin K antagonists
    Rodelo-Haad R.-H., De La Puebla Gimenez R.F., Ortega R., Rodriguez M., Aljama P.
    doi: 10.11138/ccmbm/2017.15.1.085
  15. Successful treatment of gonadotropin releasing hormone induced severe pregnancy and lactation-associated osteoporosis with teriparatide
    Tahsini Tekantapeh S., Khabbazi A.
    doi: 10.11138/ccmbm/2017.15.1.089
  16. Serious osteoporomalacia with vertebral fracturing progression in bariatric surgery: case report
    Bruno R., Seriolo C., Palermo A., Nardi A., Molfetta L.
    doi: 10.11138/ccmbm/2017.15.1.094
  17. Late diagnosis of angioleiomyoma of the knee: a case report
    Galanakos S.P., Mavrogenis A.F., Ignatiadis I., Macheras G.A.
    doi: 10.11138/ccmbm/2017.15.1.097
  18. A rare case of Melnick Needles syndrome. Case report and brief review of literature
    Mangaraj S., Choudhury A.K., Mishra I., Patro D., Baliarsinha A.K.
    doi: 10.11138/ccmbm/2017.15.1.100
  19. Coexistence of torus palatinus and acromegaly, an association with a common origin
    Morales J., Folleco M.
    doi: 10.11138/ccmbm/2017.15.1.103
  20. Thoracic and lumbar spinal stenosis in a patient with Klippel-Feil syndrome
    Igoumenou V.G., Karantzoulis V.G., Vazifehdan F.
    doi: 10.11138/ccmbm/2017.15.1.107
  21. Acute deafness as the first symptom of paraneoplastic syndrome: experience of two cases
    Wang X., Yu X.
    doi: 10.11138/ccmbm/2017.15.1.111
  22. Severe secondary osteoporosis in a premenopausal woman: should a specific treatment for osteoporosis be started?
    Baleanu F., Iconaru L., Karmali R., Body J.-J.
    doi: 10.11138/ccmbm/2017.15.1.115
  23. Osteogenesis imperfecta type V: clinico-radiological diagnosis of two cases in a limited resource setting
    Chawla M., Bhardwaj G.
    doi: 10.11138/ccmbm/2017.15.1.119
  24. Multi-organ extraosseous 99mTc-HMDP uptake in a case of metastatic melanoma
    Calandri E., Aretano I., Pultrone M., Liberatore M.
    doi: 10.11138/ccmbm/2017.15.1.123
  25. Bilateral transient osteoporosis of the hip. A case report and review of the literature
    Pallis D., Florin Georgiou D., Rizou S., Symeonidou Z., Sarzi-Puttini P., Troupis T., Casale R.
    doi: 10.11138/ccmbm/2017.15.1.128
  26. Effects of endocrine disrupting compounds on Vitamin D circulating levels
    Fossi C., Pampaloni B., Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.132
Last Viewed articles: la lista degli ultimi x visitati.
  1. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study
    Doria C., Tranquilli Leali P., Solla F., Maestretti G., Balsano M., Scarpa R.M.
    doi: 10.11138/ccmbm/2016.13.3.195
credits